The Watts Connectedness Scale: a new scale for measuring a sense of connectedness to self, others, and world
The authors developed and validated the Watts Connectedness Scale (WCS), a three‑dimensional measure of felt connectedness to self, others and the wider world that demonstrated a stable factor structure and good internal consistency. WCS scores rose significantly after psychedelic experiences—correlating with mystical, emotional‑breakthrough and communitas measures—and increased more after psilocybin therapy than escitalopram in a randomised controlled trial, indicating sensitivity to therapeutically relevant change.
Authors
- Carhart-Harris, R. L.
- Gandy, S.
- Kaelen, M.
Published
Abstract
AbstractRationaleA general feeling of disconnection has been associated with mental and emotional suffering. Improvements to a sense of connectedness to self, others and the wider world have been reported by participants in clinical trials of psychedelic therapy. Such accounts have led us to a definition of the psychological construct of ‘connectedness’ as ‘a state of feeling connected to self, others and the wider world’. Existing tools for measuring connectedness have focused on particular aspects of connectedness, such as ‘social connectedness’ or ‘nature connectedness’, which we hypothesise to be different expressions of a common factor of connectedness. Here, we sought to develop a new scale to measure connectedness as a construct with these multiple domains. We hypothesised that (1) our scale would measure three separable subscale factors pertaining to a felt connection to ‘self’, ‘others’ and ‘world’ and (2) improvements in total and subscale WCS scores would correlate with improved mental health outcomes post psychedelic use.ObjectivesTo validate and test the ‘Watts Connectedness Scale’ (WCS).MethodsPsychometric validation of the WCS was carried out using data from three independent studies. Firstly, we pooled data from two prospective observational online survey studies. The WCS was completed before and after a planned psychedelic experience. The total sample of completers from the online surveys wasN = 1226. Exploratory and confirmatory factor analysis were performed, and construct and criterion validity were tested. A third dataset was derived from a double-blind randomised controlled trial (RCT) comparing psilocybin-assisted therapy (n = 27) with 6 weeks of daily escitalopram (n = 25) for major depressive disorder (MDD), where the WCS was completed at baseline and at a 6-week primary endpoint.ResultsAs hypothesised, factor analysis of all WCS items revealed three main factors with good internal consistency. WCS showed good construct validity. Significant post-psychedelic increases were observed for total connectedness scores (η2 = 0.339,p < 0.0001), as well as on each of its subscales (p < 0.0001). Acute measures of ‘mystical experience’, ‘emotional breakthrough’, and ‘communitas’ correlated positively with post-psychedelic changes in connectedness (r = 0.42,r = 0.38,r = 0.42, respectively,p < 0.0001). In the RCT, psilocybin therapy was associated with greater increases in WCS scores compared with the escitalopram arm (ηp2 = 0.133, p = 0.009).ConclusionsThe WCS is a new 3-dimensional index of felt connectedness that may sensitively measure therapeutically relevant psychological changes post-psychedelic use. We believe that the operational definition of connectedness captured by the WCS may have broad relevance in mental health research.
Research Summary of 'The Watts Connectedness Scale: a new scale for measuring a sense of connectedness to self, others, and world'
Full Text PDF
Study Details
- Study Typeindividual
- Populationhumans
- Characteristicssurvey
- Journal
- Compound
- Topic
Cited By (24)
Papers in Blossom that reference this study
Carter, O., Castle, D., Iyer, R. et al. · Therapeutic Advances in Psychopharmacology (2025)
Albert, S., Bedi, G., Brett, J. et al. · Addiction (2025)
Carhart-Harris, R. L., Erritzoe, D., Giribaldi, B. et al. · Frontiers in Psychology (2025)
Carhart-Harris, R. L., Demetriou, L., Erritzoe, D. et al. · American Journal of Psychiatry (2025)
Carhart-Harris, R. L., Erritzoe, D., Harding, R. et al. · Molecular Psychiatry (2025)
Bola, M., Brzezicka, A., Hobot, J. et al. · Progress in Neuro-Psychopharmacology and Biological Psychiatry (2025)
Byrne, K., Garland, E. L., Hendrick, J. et al. · PLOS Medicine (2025)
Baker-Jones, M., Barba, T., Carhart-Harris, R. L. et al. · EClinicalMedicine (2024)
Goldy, S. P., Griffiths, R. R., Weiss, B. et al. · Nature Reviews Psychology (2024)
Egan, G. F., Novelli, L., Preller, K. H. et al. · Biological Psychiatry (2024)
Show all 24 papersShow fewer
D’Souza, D. C., Guss, J., Krause, R. et al. · Scientific Reports (2024)
Barba, T., Carhart-Harris, R. L., Erritzoe, D. et al. · Journal of Psychopharmacology (2024)
Barba, T., Carhart-Harris, R. L., Erritzoe, D. et al. · Scientific Reports (2024)
Agrawal, M., Beaussant, Y., Guérin, B. et al. · Cancer (2023)
Beller, N., Campbell, W. K., Erritzoe, D. et al. · Journal of Psychedelic Studies (2023)
Jacobs, E., Murphy-Beiner, A., Nutt, D. J. et al. · Neuroethics (2023)
de Wit, H., Lee, R., Lyubomirsky, S. et al. · Scientific Reports (2023)
Bentancourt, I., Bramen, J., Heinzerling, K. G. et al. · Frontiers in Psychiatry (2023)
Carhart-Harris, R. L., Monson, C. M., Wagner, A. C. et al. · Journal of Affective Disorders (2023)
Campbell, W. K., Erritzoe, D., Weiss, B. et al. · Scientific Reports (2023)
Gandy, S., Harrild, F., Irvine, A. et al. · Psychoactives (2023)
Boehnke, K. F., Kruger, D. J., Lucas, P. · International Journal of Mental Health and Addiction (2023)
Sjöstedt-Hughes, P. · Frontiers in Psychology (2023)
Cooke, J., Craste, E. G., Kałużna, A. et al. · Journal of Psychedelic Studies (2022)